OS Therapies Incorporated (OSTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OS Therapies Incorporated (OSTX) has a cash flow conversion efficiency ratio of -1.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.71 Million) by net assets ($4.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OS Therapies Incorporated (OSTX) market capitalisation for the company's overall valuation and market capitalisation.
OS Therapies Incorporated - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how OS Therapies Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OS Therapies Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OS Therapies Incorporated ranked by their cash flow conversion efficiency. See debt repayment capacity of OS Therapies Incorporated to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HS Valve Co. Ltd
KQ:039610
|
0.001x |
|
Schwälbchen Molkerei Jakob Berz AG
F:SMB
|
N/A |
|
JSS Real Estate SOCIMI SA
MC:YJSS
|
0.002x |
|
Red Pine Exploration Inc
V:RPX
|
-0.383x |
|
MeVis Medical Solutions AG
XETRA:M3V
|
0.005x |
|
Better Life Group Co Ltd
TW:1805
|
0.002x |
|
Oceanpal Inc
NASDAQ:OP
|
-0.007x |
|
Adaptimmune Therapeutics plc
F:473A
|
0.490x |
Annual Cash Flow Conversion Efficiency for OS Therapies Incorporated (2020–2024)
The table below shows the annual cash flow conversion efficiency of OS Therapies Incorporated from 2020 to 2024. View OS Therapies Incorporated share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $811.49K | $-7.28 Million | -8.974x | -7267.42% |
| 2023-12-31 | $-24.02 Million | $-3.01 Million | 0.125x | -42.04% |
| 2022-12-31 | $-17.56 Million | $-3.79 Million | 0.216x | -43.82% |
| 2021-12-31 | $-11.45 Million | $-4.40 Million | 0.384x | +0.81% |
| 2020-12-31 | $-6.33 Billion | $-2.41 Billion | 0.381x | -- |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more